Cite
HARVARD Citation
Castellano, D. et al. (2018). Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Expert opinion on drug safety. 17 (6), pp. 573-579. [Online].